Company
Biogen Inc.
Headquarters: Cambridge, MA, United States
Founded: 1978
Employees: 9,610
CEO: Mr. Michel Vounatsos
Market Cap
$19.52 Billion
USD as of July 1, 2025
Company Description
Biogen Inc. is a biotechnology company specialized in the treatment of neurological diseases. It researches, develops, and markets therapies for a range of diseases including Alzheimer’s disease, hemophilia, multiple sclerosis, spinal muscular atrophy, plaque psoriasis, leukemia, rheumatoid arthritis, lymphoma, neurocognitive disorders, and pain.
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—General
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Roche | $260.54 B |
| Novartis | $243.50 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Financials
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | $9.82 B |
| EBITDA | $3.12 B |
| Gross Profit TTM | $7.43 B |
| Profit Margin | 15.07% |
| Operating Margin | 28.05% |
| Quarterly Revenue Growth | 6.10% |
Stocks & Indices
Biogen Inc. has the following listings and related stock indices.
Stock: NASDAQ: BIIB wb_incandescent
Stock: BCBA: BIIB wb_incandescent
Stock: BMV: BIIB wb_incandescent
Stock: Bovespa: BIIB34 wb_incandescent
Stock: BVS: BIIB wb_incandescent
Stock: FSX: IDP wb_incandescent
Stock: MTA: BIIB.U wb_incandescent
Product & Services
Avonex, Fampyra, Plegridy, Tecfidera, Tysabri, Spinraza
Key People
Founder(s): Kenneth Murray Phillip Allen Sharp Walter Gilbert Heinz Schaller Charles Weissmann
Stelios Papadopoulos (Chairman) Michel Vounatsos (CEO)